Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

THE TRUTH ABOUT: Why this dividend king still stands tall - Caught on Camera

Johnson & Johnson (JNJ) remains one of the most resilient and innovative names in the healthcare industry, not just for its robust portfolio of healthcare products but also for its relentless commitment to returning value to shareholders. As of 2025, JNJ continues to carry the status of a "Dividend King," a title bestowed on companies that have consistently increased their dividend payouts for 50 consecutive years or more.

Valued at $425.3 billion, JNJ stock has surged 22% year-to-date (YTD), compared to the broader market gain.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.